Home page hero

THERE'S A LOT TO CONSIDER

WHEN PRESCRIBING AN

EXTENDED-RELEASE OPIOID

Abuse-deterrent properties do not prevent or reduce the risk of addiction.1

Abuse of OxyContin by the intravenous, intranasal, and oral routes is still possible.

Down arrow

Reference: 1. US Food and Drug Administration. Remarks delivered before FDA's scientific meeting on opioids. July 10, 2017. https://www.fda.gov/NewsEvents/Speeches/ucm566189.htm. Accessed February 21, 2018.